CCORF analyst Kyle Mikson CFA maintains $Castle Biosciences (CSTL.US)$ with a buy rating, and maintains the target price at $42.
According to TipRanks data, the analyst has a success rate of 29.3% and a total average return of -15.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Castle Biosciences (CSTL.US)$'s main analysts recently are as follows:
Castle Biosciences reported a solid third quarter, with revenues meeting expectations and encouraging operational expenditure leverage. While overall volumes increased, dermatology volumes were slightly below estimates, attributed to seasonal effects. Moreover, the TissueCypher product continued to show compelling momentum.
Attention towards coverage determination for the SCC test persists, yet it's observed that the company is advancing its volume for additional tests, including IDgenetix and TissueCypher. The robust performance of these tests played a significant role in the impressive quarterly results and the subsequent elevation in revenue guidance.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
CCORF分析師Kyle Mikson CFA維持$Castle Biosciences (CSTL.US)$買入評級，維持目標價42美元。
根據TipRanks數據顯示，該分析師近一年總勝率為29.3%，總平均回報率為-15.7%。
此外，綜合報道，$Castle Biosciences (CSTL.US)$近期主要分析師觀點如下：
castle biosciences報告了一個紮實的第三季度，營業收入符合預期，並鼓勵運營支出槓桿效應。儘管總成交量有所增加，但皮膚科成交量略低於預期，原因是季節性影響。此外，TissueCypher產品繼續展現出令人信服的增勢。
關注SCC測試的覆蓋確定仍在持續，然而，觀察到公司正在增加其他測試的量，包括 IDgenetix 和 TissueCypher。這些測試的強勁表現在令人印象深刻的季度業績以及隨後營業收入預測的提升中發揮了重要作用。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
